

Literatur zum Artikel

Prinzipien der chirurgischen Onkologie in der Viszeralchirurgie

1. Bauer KH (1949) Das Krebsproblem. Einführung in die allgemeine Geschwulstlehre für Studierende, Ärzte und Naturwissenschaftler. Springer, Heidelberg
2. Positionspapier zur chirurgischen Onkologie (1999). *Chirurg* 70: 1177
3. Bork U, Rahbari NN, Weitz J, Koch M (2014) Prinzipien der onkologischen Chirurgie und der chirurgischen Onkologie. *CHAZ* 15: 13–23
4. Zertifizierungen – Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV), www.dgav.de/savc/zertifizierungen.html
5. <https://www.bundesgesundheitsministerium.de/themen/praevention/nationaler-krebsplan/der-nationale-krebsplan-stellt-sich-vor.html>
6. <https://www.dekade-gegen-krebs.de/index.html>
7. Trautmann F, Reißfelder C, Pecqueux M, et al (2018) Evidence-based quality standards improve prognosis in colon cancer care. *Eur J Surg Oncol* 44: 1324–1330
8. Maurice MJ, Yih MJ, Ammori JB, Abouassaly R (2017) Predictors of surgical quality for retroperitoneal sarcoma: Volume matters. *J Surg Oncol* 116: 766–774
9. Keung EZ, Chiang YJ, Cormier JM, et al (2018) Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. *Cancer* 124: 4495–4503
10. <https://www.g-ba.de/presse/pressemitteilungen-meldungen/923/>
11. Brooks AD, Gold JS, Graham D, et al (2002) Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status. *Ann Surg Oncol* 9: 41–47
12. Turnbull RB Jr, Kyle K, Watson FR, Spratt J (1967) Cancer of the colon: the influence of the no-touch isolation technic on survival rates. *Ann Surg* 166: 420–427
13. Gall TMH, Jacob J, Frampton AE, et al (2014) Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. *JAMA Surgery* 149: 482–485
14. Wiggers T, Jeekel J, Arends JW, et al (1988) No-touch isolation technique in colon cancer: a controlled prospective trial. *Br J Surg* 75: 409–415
15. Hirota M, Shimada S, Yamamoto K, et al (2005) Pancreatectomy using the no-touch isolation technique followed by extensive intraoperative peritoneal lavage to prevent cancer cell dissemination: a pilot study. *JOP* 6: 143–151
16. McSorley ST, Tham A, Dolan RD, et al (2020) Perioperative blood transfusion is associated with postoperative systemic inflammatory response and poorer outcomes following surgery for colorectal cancer. *Ann Surg Oncol* 27: 833–843
17. Pang QY, An R, Liu HL (2019) Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis. *World J Surg Oncol* 17: 7
18. Mynster T, Christensen IJ, Moesgaard F, Nielsen HJ (2000) Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. *Br J Surg* 87: 1553–1562
19. Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet* 1 (8496): 1479–1482
20. MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. *Lancet* 341(8843): 457–460
21. Bogner A, Kirchberg J, Weitz J, Fritzmann J (2019) State of the art – rectal cancer surgery. *Visc Med* 35: 252–258.
22. Guo J, Xu A, Sun X, et al (2019) Combined surgery and extensive intraoperative peritoneal lavage vs surgery alone for treatment of locally advanced gastric cancer: the SEIPLUS randomized clinical trial. *JAMA Surg* 154: 610–616
23. Bertelsen CA, Neuenschwander AU, Jansen JE, et al (2015) Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. *Lancet Oncol* 16: 161–168
24. Kang CM, Suh KS, Yi NJ, et al (2021) Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea-Japan Study. *Cancers (Basel)* 13: 445
25. Bartsch F, Heinrich S, Roth W, Lang H (2019) Lymphadenektomie in der onkologischen Viszeralchirurgie – Teil I. *Chirurg* 90: 423–438
26. Bembek A, String A, Gretschel S, Schlag PM (2008) Technique and clinical consequences of sentinel lymph node biopsy in colorectal cancer. *Surg Oncol* 17: 183–193
27. Matsuda T, Takeuchi H, Tsuwano S, et al (2014) Sentinel node mapping in adenocarcinoma of the esophagogastric junction. *World J Surg* 38: 2337–2344
28. Thompson SK, et al (2011) Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy. *Surg Endosc* 25: 817–825
29. de Haas RJ, Wicherts DA, Hobbelen MGG, et al (2007) Sentinel lymph node mapping in colon cancer: current status. *Ann Surg Oncol* 14: 1070–1080
30. Seymour MT, Morton D, o.b.o.t.i.F.T. Investigators (2019) FOXTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. *J Clin Oncol* 37: 3504–3504
31. Cunningham D, Allum WH, Stenning SP, et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 355: 11–20
32. Al-Batran SE, Homann N, Pauligk C, et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 393(10184): 1948–1957
33. Bahadoer RR, Dijkstra EA, van Etten B, et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. *Lancet Oncol* 22: 29–42
34. Garcia-Aguilar J, Patil S, Kim JK, et al (2020) Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. *J Clin Oncol* 38: 4008–4008
35. Conroy T, Lamfichekh N, Etienne PL, et al (2020) Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. *J Clin Oncol* 38: 4007–4007
36. Ferrone CR, Brennan MF, Gonen M, et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. *J Gastrointest Surg* 12: 701–706
37. Hackert T, Sachsenmaier M, Hinz U, et al (2016) Locally advanced pancreatic cancer: neoadjuvant therapy with folfinox results in resectability in 60% of the patients. *Ann Surg* 264: 457–463
38. Ferrone CR, Marchegiani G, Hong TS, et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. *Ann Surg* 261: 12–17
39. Ettrich TJ, Berger AW, Perkhof L, et al (2018) Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. *BMC Cancer* 18: 1298
40. Cucchetti A, Ferrero A, Cescon M, et al (2015) Cure model survival analysis after hepatic resection for colorectal liver metastases. *Ann Surg Oncol* 22: 1908–1914
41. Al-Batran SE, Goetze TO, Mueller DW, et al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. *BMC Cancer* 17: 893
42. Jung MK, Ott K, Chevally M, Mönig SP (2021) Therapieoptionen beim oligometastasierten Magenkarzinom. *Chirurg*. <https://doi.org/10.1007/s00104-021-01353-5> (online first)

43. Hau HM, Tautenhahn HM, Schoenberg MB, et al (2014) Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study. *Anticancer Res* 34: 6633–6639
44. Knitter S, Andreou A, Kradolfer D, et al (2020) Minimal-Invasive Versus Open Hepatectomy for Colorectal Liver Metastases: Bicentric Analysis of Postoperative Outcomes and Long-Term Survival Using Propensity Score Matching Analysis. *J Clin Med* 9: 4027
45. Green BL, Marschall HC, Collinson F, et al (2013) Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg* 100: 75–82
46. Jayne DG, Thorpe HC, Copeland J, et al (2010) Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg* 97: 1638–1645
47. Nuytens F, Dabakuyo-Yonli TS, Meunier B, et al (2021) Five-year survival outcomes of hybrid minimally invasive esophagectomy in esophageal cancer: results of the MIRO randomized clinical trial. *JAMA Surg*. doi: 10.1001/jamasurg.2020.7081 (in Druck)
48. Zureikat A, Moser AJ, Boone BA, et al (2013) 250 robotic pancreatic resections: safety and feasibility. *Ann Surg* 258: 554–559
49. Zureikat AH, Postlewait JM, Liu Y, et al (2016) A Multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. *Ann Surg* 264: 640–649
50. Wabitsch S, Kaestner A, Haber PK, et al (2019) Laparoscopic versus open liver resection for benign tumors and lesions: a case matched study with propensity score matching. *J Laparoendosc Adv Surg Tech A* 29: 1518–1525
51. van der Sluis PC, Ruurda JP, van der Horst, et al (2012) Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial). *Trials* 13: 230
52. Kirchberg J, Weitz J (2019) Evidenz der Roboter-Chirurgie in der onkologischen Viszeralchirurgie. *Chirurg* 90: 379–386
53. Dinmohamed AG, Visser O, Verhoeven RHA, et al (2020) Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. *Lancet Oncol* 21: 750–751
54. Dinmohamed AG, Cellamare M, Visser O, et al (2020) The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. *J Hematol Oncol* 13: 147
55. Uyl-de Groot CA, Schuurman MS, Huijgens PC, Praagman J et al (2020) Fewer cancer diagnoses during the COVID-19 epidemic according to diagnosis, age and region. *TSG*: 1–8
56. Morris EJA, Goldacre R, Spata E, et al (2021) Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. *Lancet Gastroenterol Hepatol* 6: 199–208
57. Turnbull C (2021) Effect of COVID-19 on colorectal cancer care in England. *Lancet Gastroenterol Hepatol* 6: 152–154